Arcturus Therapeutics
ARCT
165 hedge funds and large institutions have $802M invested in Arcturus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 52 increasing their positions, 54 reducing their positions, and 14 closing their positions.
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
25% more capital invested
Capital invested by funds: $643M → $802M (+$159M)
14% more funds holding
Funds holding: 145 → 165 (+20)
0.73% more ownership
Funds ownership: 94.42% → 95.16% (+0.73%)
1% less call options, than puts
Call options by funds: $9.75M | Put options by funds: $9.89M
4% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7M |
| 2 |
BlackRock
New York
|
+$6.19M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$4.92M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$3.98M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.55M |
| 2 |
Renaissance Technologies
New York
|
-$4.03M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.51M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.11M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.86M |
ARCT Hedge Fund Activity: Q4 2023 in Review
165 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2023, worth a combined $802M — up 25% from $643M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ARCT positions and 14 closed out — a net gain of 22 holders — while 52 added to existing stakes and 54 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $7M. The largest seller was Point72 Asset Management, cutting an estimated $7.55M.
- 165 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2023, up from 145 in Q3 2023.
- Funds reported $802M of Arcturus Therapeutics stock for Q4 2023, up 25% quarter-over-quarter.
- 36 funds opened new Arcturus Therapeutics positions in Q4 2023 and 14 closed out, a net change of +22 holders.
- The largest Arcturus Therapeutics buyer in Q4 2023 was Schonfeld Strategic Advisors, an estimated $7M added.
- The largest Arcturus Therapeutics seller in Q4 2023 was Point72 Asset Management, an estimated $7.55M sold.
Based on aggregated 13F filings for Q4 2023.